Year |
Citation |
Score |
2023 |
Webber BR, Johnson MJ, Skeate JG, Slipek NJ, Lahr WS, DeFeo AP, Mills LJ, Qiu X, Rathmann B, Diers MD, Wick B, Henley T, Choudhry M, Starr TK, McIvor RS, et al. Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair. Nature Biomedical Engineering. PMID 38092857 DOI: 10.1038/s41551-023-01157-4 |
0.405 |
|
2023 |
Rollins MR, Raynor JF, Miller EA, Butler JZ, Spartz EJ, Lahr WS, You Y, Burrack AL, Moriarity BS, Webber BR, Stromnes IM. Germline T cell receptor exchange results in physiological T cell development and function. Nature Communications. 14: 528. PMID 36726009 DOI: 10.1038/s41467-023-36180-1 |
0.309 |
|
2022 |
Laoharawee K, Johnson MJ, Lahr WS, Sipe CJ, Kleinboehl E, Peterson JJ, Lonetree CL, Bell JB, Slipek NJ, Crane AT, Webber BR, Moriarity BS. A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes. International Journal of Molecular Sciences. 23. PMID 36077152 DOI: 10.3390/ijms23179749 |
0.32 |
|
2022 |
Sipe CJ, Kluesner MG, Bingea SP, Lahr WS, Andrew AA, Wang M, DeFeo AP, Hinkel TL, Laoharawee K, Wagner JE, MacMillan ML, Vercellotti GM, Tolar J, Osborn MJ, McIvor RS, ... Webber BR, et al. Correction of Fanconi Anemia Mutations Using Digital Genome Engineering. International Journal of Molecular Sciences. 23. PMID 35955545 DOI: 10.3390/ijms23158416 |
0.709 |
|
2021 |
Kramer A, Astuti Y, Elfstrum A, Lehrke MJ, Tolar J, Blazar BR, Blake A, Taisto M, Furcich JW, Nolan EE, Durose WW, Webber BR, Geisness A, Wood DK, Lund T. An irradiated marrow niche reveals a small non-collagenous protein mediator of homing, dermatopontin. Blood Advances. PMID 34448828 DOI: 10.1182/bloodadvances.2021004475 |
0.451 |
|
2021 |
Kluesner MG, Lahr WS, Lonetree CL, Smeester BA, Qiu X, Slipek NJ, Claudio Vázquez PN, Pitzen SP, Pomeroy EJ, Vignes MJ, Lee SC, Bingea SP, Andrew AA, Webber BR, Moriarity BS. CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nature Communications. 12: 2437. PMID 33893286 DOI: 10.1038/s41467-021-22009-2 |
0.362 |
|
2020 |
Laoharawee K, Johnson MJ, Lahr WS, Peterson JJ, Webber BR, Moriarity BS. Genome Engineering of Primary Human B Cells Using CRISPR/Cas9. Journal of Visualized Experiments : Jove. PMID 33226023 DOI: 10.3791/61855 |
0.371 |
|
2020 |
Wierson WA, Welker JM, Almeida MP, Mann CM, Webster DA, Torrie ME, Weiss TJ, Kambakam S, Vollbrecht MK, Lan M, McKeighan KC, Levey J, Ming Z, Wehmeier A, Mikelson CS, ... ... Webber BR, et al. Efficient targeted integration directed by short homology in zebrafish and mammalian cells. Elife. 9. PMID 32412410 DOI: 10.7554/Elife.53968 |
0.378 |
|
2019 |
Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BA, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS. Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications. 10: 5659. PMID 31811147 DOI: 10.1038/S41467-019-13778-Y |
0.62 |
|
2019 |
Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BS, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications. 10: 5222. PMID 31745080 DOI: 10.1038/S41467-019-13007-6 |
0.686 |
|
2019 |
Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, Lonetree CL, Yamamoto K, Bendzick L, Miller JS, Geller MA, Walcheck B, Felices M, Webber BR, Starr TK, et al. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31704085 DOI: 10.1016/J.Ymthe.2019.10.009 |
0.349 |
|
2019 |
Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, Xia L, Chen W, Eide CR, Webber BR, Wandall HH, Dabelsteen S, Blazar BR, Liu DR, Tolar J. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. The Journal of Investigative Dermatology. PMID 31437443 DOI: 10.1016/J.Jid.2019.07.701 |
0.715 |
|
2019 |
Matson JP, Dumitru R, Coryell P, Baxley RM, Chen W, Twaroski K, Webber BR, Tolar J, Bielinsky AK, Purvis JE, Cook JG. Correction: Rapid DNA replication origin licensing protects stem cell pluripotency. Elife. 8. PMID 31166167 DOI: 10.7554/Elife.49040 |
0.316 |
|
2018 |
Johnson MJ, Laoharawee K, Lahr WS, Webber BR, Moriarity BS. Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. Scientific Reports. 8: 12144. PMID 30108345 DOI: 10.1038/S41598-018-30358-0 |
0.301 |
|
2018 |
Osborn MJ, Lees CJ, McElroy AN, Merkel SC, Eide CR, Mathews W, Feser CJ, Tschann M, McElmury RT, Webber BR, Kim CJ, Blazar BR, Tolar J. CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. International Journal of Molecular Sciences. 19. PMID 29565806 DOI: 10.3390/Ijms19040946 |
0.711 |
|
2018 |
Webber B, Lonetree C, Diers M, Lahr WS, Mitchell K, Johnson MJ, Moriarity BS. Multiplex Human T Cell Engineering without Double-Strand Break Induction Using the Cas9 Base Editor System Blood. 132: 3495-3495. DOI: 10.1182/Blood-2018-99-120372 |
0.529 |
|
2018 |
Emily P, John H, Mitchell K, Margaret C, Bendzick L, Miller JS, Webber B, Geller MA, Felices M, Starr T, Moriarity BS. Enhancing Human NK Cell Function and Specificity for Cancer Immunotherapy Blood. 132: 2044-2044. DOI: 10.1182/Blood-2018-99-120173 |
0.442 |
|
2017 |
Webber BR, O'Connor KT, McElmurry RT, Durgin EN, Eide CR, Lees CJ, Riddle MJ, Mathews WE, Frank NY, Kluth MA, Ganss C, Moriarity BS, Frank MH, Osborn MJ, Tolar J. Rapid generation of Col7a1(-/-) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28892093 DOI: 10.1038/Labinvest.2017.85 |
0.665 |
|
2017 |
Skvarova Kramarzova K, Osborn MJ, Webber BR, DeFeo AP, McElroy AN, Kim CJ, Tolar J. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. International Journal of Molecular Sciences. 18. PMID 28613254 DOI: 10.3390/Ijms18061269 |
0.711 |
|
2017 |
Angelos MG, Ruh PN, Webber BR, Blum RH, Ryan CD, Bendzick L, Shim S, Yingst AM, Tufa DM, Verneris MR, Kaufman DS. Aryl hydrocarbon receptor inhibition promotes hemato-lymphoid development from human pluripotent stem cells. Blood. PMID 28533309 DOI: 10.1182/blood-2016-07-730440 |
0.36 |
|
2016 |
Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, Xia L, Eide C, Lees CJ, McElmurry RT, Riddle MJ, Kim CJ, Patel DD, Blazar BR, Tolar J. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. Npj Regenerative Medicine. 1. PMID 28250968 DOI: 10.1038/Npjregenmed.2016.14 |
0.721 |
|
2016 |
Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J, Braunlin EA. Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. Journal of Inherited Metabolic Disease. PMID 27743312 DOI: 10.1007/S10545-016-9988-Z |
0.596 |
|
2016 |
Osborn M, Lonetree CL, Webber BR, Patel D, Dunmire S, McElroy AN, DeFeo AP, MacMillan ML, Wagner J, Balzar BR, Tolar J. CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem Cells and Development. PMID 27538887 DOI: 10.1089/scd.2016.0149 |
0.709 |
|
2016 |
Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, et al. Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 570-81. PMID 26502778 DOI: 10.1038/Mt.2015.197 |
0.68 |
|
2016 |
Webber B, O’Connor K, McElmurry R, Durgin E, Riddle M, Osborn M, Tolar J. 419 Efficient CRISPR/Cas9-mediated knockout of Col7a1 in NOD/SCID IL2Rgamma-null mice by pro-nuclear injection Journal of Investigative Dermatology. 136: S74. DOI: 10.1016/J.Jid.2016.02.453 |
0.579 |
|
2016 |
Osborn M, Webber B, McElroy A, Defeo A, Patel D, Lees C, McElmurry R, Riddle M, Blazar B, Tolar J. 371 CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa (RDEB) Journal of Investigative Dermatology. 136: S66. DOI: 10.1016/J.Jid.2016.02.404 |
0.627 |
|
2015 |
Smith MJ, Webber BR, Mohtashami M, Stefanski HE, Zún˜iga-Pflücker JC, Blazar BR. Concise Review: In Vitro T-Cell Generation from Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination. Stem Cells (Dayton, Ohio). PMID 26227158 DOI: 10.1002/Stem.2115 |
0.501 |
|
2015 |
Webber BR, Tolar J. From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 987-92. PMID 25803200 DOI: 10.1038/mt.2015.47 |
0.333 |
|
2015 |
Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi anemia gene editing by the CRISPR/Cas9 system. Human Gene Therapy. 26: 114-26. PMID 25545896 DOI: 10.1089/Hum.2014.111 |
0.689 |
|
2015 |
Osborn MJ, Webber BR, Knipping F, Lonetree C, DeFeo A, McElroy A, Starker C, Gabriel R, Merkel S, Hippen KL, Voytas D, von Kalle C, Schmidt M, Miller JS, Jarjour J, et al. Megatal, Crispr/Cas9, and Talen T-Cell Receptor Gene Editing Blood. 126: 2045-2045. DOI: 10.1182/Blood.V126.23.2045.2045 |
0.715 |
|
2015 |
Webber BR, Tolar J, Kyba M, Blazar BR. Targeted single copy Runx1 reporter lines for interrogation and enhancement of definitive hematopoiesis from murine pluripotent stem cells Experimental Hematology. 43: S100. DOI: 10.1016/J.Exphem.2015.06.278 |
0.465 |
|
2013 |
Webber BR, Iacovino M, Choi SH, Tolar J, Kyba M, Blazar BR. DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo. Blood. 122: 2978-86. PMID 24030384 DOI: 10.1182/Blood-2013-03-489369 |
0.39 |
|
2013 |
Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, et al. TALEN-based gene correction for epidermolysis bullosa. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1151-9. PMID 23546300 DOI: 10.1038/Mt.2013.56 |
0.717 |
|
2011 |
Tolar J, Park IH, Xia L, Lees CJ, Peacock B, Webber B, McElmurry RT, Eide CR, Orchard PJ, Kyba M, Osborn MJ, Lund TC, Wagner JE, Daley GQ, Blazar BR. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. 117: 839-47. PMID 21037085 DOI: 10.1182/Blood-2010-05-287607 |
0.696 |
|
Show low-probability matches. |